Product Description
Azelaprag (AMG 986) is an apelin receptor agonist that is claimed in Amgen's patent WO2016187308A1 (as example 263) [2]. The chemical structure is identical to that submitted to the WHO for the INN azelaprag. Apelin receptor agonists are being pursued for their clinical inotropic potential in the treatment of heart failure. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10061)
Mechanisms of Action: APJ Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: New Zealand
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Obesity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06141889 |
BGE-105-004 | P1 |
Completed |
Obesity |
2024-01-26 |
69% |
2024-02-24 |
Primary Endpoints |